Please assess the completion status of the following clinical trial:

Trial Title: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Histologic diagnosis of melanoma.~2. Unresectable Stage III or IV disease~3. Documented progressive disease based on radiographic, clinical or pathologic assessment.~4. No more than three prior anticancer regimens (BRAF/MEK inhibitors, IL-2 or investigational agents) including no more than one chemotherapy-containing regimen for advanced (recurrent, locally advanced or metastic) disease.~5. Measurable disease.~6. Life expectancy ≥ 12 weeks.~7. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment.~8. Availability of tumor tissue for central laboratory analyses.~Key Exclusion Criteria:~1. Previous treatment with anti-CD27 antibody, ipilimumab or other anti-CTLA-4 targeted therapies. Previous therapy with other checkpoint blockers such as anti-PD-1 or anti-PD-L1 is acceptable, unless treatment was discontinued for intolerance.~2. For patients enrolled to Phase II Cohort B: Previous administration of vaccine therapy targeting NY-ESO-1.~3. BRAF/MEK inhibitors within 2 weeks prior to first dose of study treatment.~4. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment.~5. Monoclonal based therapies within 4 weeks and all other immunotherapy within 2 weeks prior to first dose of study treatment.~6. Systemic radiation therapy within 4 weeks, focal radiotherapy within 2 weeks and radiopharmaceuticals (strontium, samarium) within 8 weeks prior to first dose of study treatment.~7. Ocular Melanoma~8. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years.~9. Active, untreated central nervous system metastases.~10. Active autoimmune disease or documented history of autoimmune disease.~11. Active diverticulitis~12. Significant cardiovascular disease including CHF or poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase l: varlilumab and ipilimumab (Type: EXPERIMENTAL): None
- Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).